Conditions: Indolent Non-Hodgkin's Lymphoma Follicular Lymphoma Small Lymphocytic Lymphoma Marginal Zone Lymphoma
Keywords: Indolent Non-Hodgkin's Lymphoma Non-Hodgkin Lymphoma iNHL NHL CAL-101 PI3K Phosphatidylinositol 3-kinase Follicular Lymphoma (FL) Small Lymphocytic Lymphoma (SLL) Marginal Zone Lymphoma (MZL)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
The primary objectives of this study is to evaluate the safety and efficacy of idelalisib (GS-1101, CAL-101) in participants with previously treated indolent non-Hodgkin lymphoma (iNHL).

Eligible patients will initiate oral therapy with idelalisib at a starting dose of 150 mg twice per day. Treatment with idelalisib can continue in compliant participants for up to twelve 28-day cycles of idelalisib. Participants who appear to be benefiting from treatment at the completion of 12 cycles of treatment with idelalisib may be eligible for participation in a long-term safety extension study of idelalisib.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Idelalisib
Intervention descriptions: intervention 1: Tablet(s) administered orally twice daily

Protocol document: